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Th   e rapid development of nanomedicine oﬀ  ers innovative 
approaches to improving current cancer diagnostic and 
therapeutic technologies [1,2]. Among the numerous 
challenges faced by the ﬁ  eld of oncology, more eﬃ   ciently 
controlled drug release and drug penetration into solid 
tumors are now thought possible by the use of magnetic 
nanoparticles [3-6]. A recent study by Kong and colleagues 
[7] documents the successful creation of a drug delivery 
system using nanocapsules that provide on-demand drug 
release by external magnetic stimuli. Th  is technology 
provides the ability to remotely and repeatedly release an 
anticancer drug while in the ‘on’ state, but safely contain 
the drug within the delivery vehicle in the ‘oﬀ  ’ state.
Porous silica magnetic nanocapsules (SiMNCs; 100 to 
150 nm in diameter) are synthesized with iron oxide 
(Fe3O4) nanoparticles and anticancer drug molecules, 
such as camptothecin and doxorubicin, intentionally 
trapped within their hollow interiors. By remotely 
applying an external switchable on-oﬀ    radiofrequency 
(RF) ﬁ  eld, controlled release of the anticancer drugs is 
achieved. Th  e authors propose that localized heating of 
the iron oxide nanoparticles occurs in a manner similar 
to the phenomenon observed in RF-induced magnetic 
hyperthermia of cancer cells [8]. Th   is increase in 
temperature likely causes accelerated diﬀ  usion and sub-
se  quent release of the drugs. Th   e proposed mecha  nism is 
visually conﬁ   rmed by the controlled release of a 
ﬂ   uorophore (9,10-bis(phenylethynyl)anthracene) from 
the SiMNCs upon RF magnetic ﬁ  eld exposure, suggesting 
that various molecular cargos can be potentially loaded 
into and delivered by the SiMNCs.
Due to the nanoscale conﬁ   nement of the magnetic 
nanoparticles within their interior, the SiMNCs exhibit 
enhanced magnetic properties when compared to iron 
oxide nanoparticles. Th  is enhanced magnetization is 
exploited to facilitate tumor penetration as deep as 
approximately ten cell thicknesses (approximately 50 μm) 
within MT2 mouse breast cancer cell colonies in a 
gradient magnetic ﬁ   eld (approximately 1,200 Oe) for 
2  hours. Upon on-oﬀ    RF ﬁ   eld exposure, a signiﬁ  cant 
decrease in tumor cell viability is observed, suggesting 
successful drug release into the tumor site. Similarly, in 
vivo studies revealed that the SiMNCs can accumulate at 
a breast tumor site after being intravenously administered 
into tumor-bearing mice. With a magnet placed in 
contact with the skin above the tumor site for 2 hours, 
the average number of SiMNCs trapped in a tumor was 
200 times more than for the control.
Th  e advantages of this drug delivery technology are 
highly promising for cancer therapy. First, the system 
provides a highly eﬃ   cient means to safely deliver anti-
cancer drugs to deep tumor sites via magnetic targeting. 
As noted by the authors, the majority of the administered 
nanocapsules reach the target site with minimal amounts 
accumulated in the liver and spleen. Secondly, the silica 
shell and drug payload of the SiMNCs can be modiﬁ  ed to 
allow for customizable drug administration. Th  e  exterior 
of the porous silica shell can be covalently functionalized 
with various biomolecules for targeting purposes. In 
addition to anticancer drugs and ﬂ  uorophores,  other 
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hormones, can be potentially loaded into and released 
from the SiMNC particles. Lastly, the magnetic nano-
particles within the SiMNCs are superparamagnetic and 
can therefore be visualized by T2-weighted MRI. Th  is 
capability should be further explored in order to assess 
SiMNCs as eﬀ  ective ‘theranostic’ agents.
One drawback in the system design is the inability to 
target tumors that have not yet been located or those that 
are not superﬁ  cially accessible. Currently, the location of 
the tumor must be known so that an external magnetic 
ﬁ   eld can be applied to the target area to allow for 
nanocapsule accumulation. Th  e MRI capability of the 
iron oxide nanoparticles and the possibility of attaching 
targeting groups to the SiMNC exterior may remedy this 
limitation. Th   e SiMNCs may not eﬃ   ciently target a deep-
tissue tumor since the applied magnetic ﬁ  eld strength 
decreases with distance, and this could lead to drug 
accumulation in the region between the external magnet 
and the tumor. Surgically implanting a magnet closer to 
the tumor site, as demonstrated in similar studies [9], is a 
possible way to circumvent this problem.
Several issues must be addressed before clinical imple-
mentation. It is important to determine whether the 
release of the drug payload is a result of localized heating 
of the magnetic nanoparticles or an increase in the 
ambient temperature of the SiMNC surroundings. As the 
authors suggest, a quantitative analysis of the heat 
genera  tion and conduction within the nanocapsules is 
necessary to better understand the drug release mecha-
nism. Furthermore, it must also be conﬁ  rmed that the 
cell death observed after RF treatment is due only to drug 
release and not to magnetic hyperthermia produced by 
the magnetic nanoparticles. As all other nanoparticles, 
the biodistribution, biodegradation, and in vivo eﬃ   ciency 
of the SiMNCs under more strenuous physiological 
conditions, such as blood ﬂ  ow, must also be evaluated 
before use in human patients can be realized.
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